An integrated strategy for revealing the pharmacological changes based on metabolites profiling and network pharmacology: Arctiin as an example

被引:25
|
作者
Zhang, Feng-xiang [1 ,2 ]
Li, Zi-ting [3 ]
Li, Min [3 ]
Yuan, Yu-lin-lan [1 ]
Cui, Shuang-shuang [1 ]
Wang, Guan-hua [4 ]
Li, Rui-man [1 ]
机构
[1] Jinan Univ, Affiliated Hosp 1, Dept Gynaecol & Obstet, Guangzhou 510632, Peoples R China
[2] Jinan Univ, Sch Tradit Chinese Med, Formula Pattern Res Ctr, Guangzhou 510632, Peoples R China
[3] Jinan Univ, Coll Pharm, Inst Tradit Chinese Med & Nat Prod, Guangzhou 510632, Peoples R China
[4] South China Agr Univ, Coll Vet Med, Guangzhou 510642, Peoples R China
关键词
Arctiin; Fructus Arctii; Metabolites profiling; Network pharmacology; UHPLC-Q-TOF MS; IN-VIVO; ARCTIGENIN; IDENTIFICATION; TRANSFORMATION; PLATFORM; PLASMA; TISSUE;
D O I
10.1016/j.jchromb.2020.122270
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Traditional Chinese medicine was widely used in China since its definite effects and therapy. The components of TCM were absorbed into the circle system as the format of prototypes or metabolites, which contributed to the therapy or side effects. Declaring the functional changes in this process was of great importance to the clinical applications. In this work, an integrated strategy based on metabolites' profiling and network pharmacology was proposed for exploring the pharmacological changes of compounds in vivo. Arctiin, the main component in Fructus Arctii with various kinds of bioactivities, was used as an example. An ultra-performance liquid chromatography coupled with time-of-flight mass spectrometry and metabolynx (TM) software was applied to characterize the metabolites of arctiin in rats at a dosage of 100 mg/kg; network pharmacology was applied to characterize the functional changes. As a result, fifty-three metabolites (32 in plasma, 40 in urine, 19 in bile, 20 in feces, 1 in brain, 12 in liver and 4 in lungs) were screened out and characterized, and 3 of them were unambitiously identified by comparison with standard substances. Among them, 38 metabolites were reported for the first time. It was found the major metabolic pathways of arctiin in rats were demethylation, lactoneopening and phase II conjugations with sulfate and glucuronide. It also confirmed that M14, M15, M18, M23, M22, M43 and M45 were the major circulating forms of arctiin in rats following oral administration. In addition to the above metabolic reactions, phase I reactions of hydrolysis, demethylation, dehydroxylation were also observed, and dehydrogenation were first revealed metabolic patterns of arctiin in rats. Meanwhile, in addition to the main targets of arctiin (MTOR, EGFR and MAPK14), its metabolites targeted additional 392 targets with additional functions of anti-hepatitis B or viral carcinogenesis (SRC, CAPS3, PIK3CA, CDK4, ESR1, MMP9 and ERBB2). The above results provided very important information for understanding the metabolism and functional changes of arctiin in vivo, and supporting data for further pharmacological evaluation. Our work also provided a newsight for elucidation of functional changes of TCMs in vivo.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Revealing the Pharmacological Mechanism of Acorus tatarinowii in the Treatment of Ischemic Stroke Based on Network Pharmacology
    Liu, FengZhi
    Zhao, Qian
    Liu, Suxian
    Xu, Yingzhi
    Zhou, Dongrui
    Gao, Ying
    Zhu, Lingqun
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2020, 2020
  • [2] Revealing the potential pharmacological mechanism of traditional Chinese medicine by integrating metabolite profiling of a Q-marker and network pharmacology, prim-O-glucosylcimifugin as an example
    Zhang, Feng-Xiang
    Yuan, Yu-Lin-Lan
    Cui, Shuang-Shuang
    Wang, Guan-Hua
    Li, Rui-Man
    NEW JOURNAL OF CHEMISTRY, 2021, 45 (34) : 15571 - 15581
  • [3] A combination of metabolite profiling and network pharmacology to explore the potential pharmacological changes of secoisolariciresinol-diglycoside
    Zhang, Fengxiang
    Cui, ShuangShuang
    Li, Ziting
    Yuan, Yulinlan
    Li, Chang
    Li, Ruiman
    RSC ADVANCES, 2020, 10 (57) : 34847 - 34858
  • [4] Network pharmacology and pharmacokinetics integrated strategy to investigate the pharmacological mechanism of Xianglian pill on ulcerative colitis
    Liu, Chang-Shun
    Xia, Ting
    Luo, Zhen-Ye
    Wu, Yuan-Yuan
    Hu, Yan-Nan
    Chen, Fei-Long
    Tang, Qing-Fa
    Tan, Xiao-Mei
    PHYTOMEDICINE, 2021, 82
  • [5] Network pharmacology and molecular docking integrated strategy to investigate the pharmacological mechanism of palmatine in Alzheimer's disease
    Pei, Hongyan
    Zeng, Jianning
    Chen, Weijia
    He, Zhongmei
    Du, Rui
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2022, 36 (11)
  • [6] Network pharmacology-based strategy to investigate pharmacological mechanisms of Zuojinwan for treatment of gastritis
    Yu, Guohua
    Wang, Wubin
    Wang, Xu
    Xu, Meng
    Zhang, Lili
    Ding, Lei
    Guo, Rui
    Shi, Yuanyuan
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2018, 18
  • [7] Network pharmacology-based strategy to investigate pharmacological mechanisms of Zuojinwan for treatment of gastritis
    Guohua Yu
    Wubin Wang
    Xu Wang
    Meng Xu
    Lili Zhang
    Lei Ding
    Rui Guo
    Yuanyuan Shi
    BMC Complementary and Alternative Medicine, 18
  • [8] Integrated strategy for accurately screening biomarkers based on metabolomics coupled with network pharmacology
    Zhang, Wendan
    Chen, Yu
    Jiang, Honghong
    Yang, Jianxi
    Wang, Qiao
    Du, Yingfeng
    Xu, Huijun
    TALANTA, 2020, 211
  • [9] Revealing the pharmacological effects of Remodelin against osteosarcoma based on network pharmacology, acRIP-seq and experimental validation
    Gao, Jia
    Xu, Peili
    Wang, Feng
    Zhang, Wenjie
    Min, Meipeng
    Urba, Rafi
    Fan, Lei
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [10] Exploring the pharmacological and adverse reaction mechanism of a drug by network pharmacology strategy Using colchicine to treat Behcet syndrome as an example
    Li, Shizhe
    Wang, Lei
    Wang, Yeming
    Zhang, Chaoqun
    MEDICINE, 2023, 102 (14) : E33486